NOVO.B.DK

263.65

+0.84%↑

GMAB.DK

1,708.5

-0.41%↓

COLO.B.DK

405.8

-1.86%↓

ZEAL.DK

302.4

-0.4%↓

AMBUB.DK

65.05

-0.23%↓

NOVO.B.DK

263.65

+0.84%↑

GMAB.DK

1,708.5

-0.41%↓

COLO.B.DK

405.8

-1.86%↓

ZEAL.DK

302.4

-0.4%↓

AMBUB.DK

65.05

-0.23%↓

NOVO.B.DK

263.65

+0.84%↑

GMAB.DK

1,708.5

-0.41%↓

COLO.B.DK

405.8

-1.86%↓

ZEAL.DK

302.4

-0.4%↓

AMBUB.DK

65.05

-0.23%↓

NOVO.B.DK

263.65

+0.84%↑

GMAB.DK

1,708.5

-0.41%↓

COLO.B.DK

405.8

-1.86%↓

ZEAL.DK

302.4

-0.4%↓

AMBUB.DK

65.05

-0.23%↓

NOVO.B.DK

263.65

+0.84%↑

GMAB.DK

1,708.5

-0.41%↓

COLO.B.DK

405.8

-1.86%↓

ZEAL.DK

302.4

-0.4%↓

AMBUB.DK

65.05

-0.23%↓

Kodu・Aktsiate loetelu・H Lundbeck A-S

H
H Lundbeck A-S

Suletud

43.88 -0.9

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

43.36

Max

44.34

Põhinäitajad
By Trading Economics
Sissetulek	-1.7B -27M
Müük	-465M 5.8B
P/E Sektori keskmine	13.503 60.328
Aktsiakasum	0.94
Dividenditootlus	2.71
Kasumimarginaal	-0.464
Töötajad	5,039
EBITDA	130M 1.8B

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	2.71% 2.24%

Turustatistika
By TradingEconomics
Turukapital	2.7B 43B
Eelmine avamishind	44.78
Eelmine sulgemishind	43.88

H Lundbeck A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27. apr 2026, 23:08 UTC

Tulu

Suurimad hinnamuutused turgudel

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27. apr 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27. apr 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27. apr 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27. apr 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27. apr 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27. apr 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27. apr 2026, 22:10 UTC

Tulu

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27. apr 2026, 21:56 UTC

Tulu

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27. apr 2026, 21:44 UTC

Tulu

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27. apr 2026, 21:43 UTC

Tulu

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. apr 2026, 20:39 UTC

Tulu

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Võrdlus sarnastega

Hinnamuutus

H Lundbeck A-S Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.